TABLE 4.
Virological parameters and CD4 T cell levels of HIV-2+ patients under ARTd
| Case no. | Current ART regimen | Follow-up after HIV diagnosis/under ART (mo)a | CD4 T pre-ART; post-ART (cells/μl)a | Mutations | Viremia (RNA copies/ml) | Proviral DNA (copies/106 PBMC) | tat mRNA (arbitrary units) | gag mRNA (arbitrary units) |
|---|---|---|---|---|---|---|---|---|
| 1 | d4T + 3TC + SQV/rb | 177/108 | 300; 719 | NA | 4,172 | 5 | Undet | 1.07 × 102 |
| 2 | AZT/3TC/ABC | 63/63 | 138; 554 | NA | <40 | 5 | Undet | 9.82 × 101 |
| 3 | AZT/3TC | 26/26 | 457; 535 | PR + RTc | <40 | 5 | 2.13 × 101 | Undet |
| 4 | AZT/3TCb | 206/64 | 500; 520 | NA | 44 | 158 | Undet | Undet |
| 5 | AZT/3TC + LPV/r | 126/26 | 125; 457 | NA | <40 | 114 | Undet | 3.56 × 102 |
| 6 | AZT/3TC + LPV/r | 38/28 | 164; 406 | NA | <40 | 108 | Undet | 4.46 × 101 |
| 7 | AZT/3TC/ABC | 242/61 | 287; 340 | PR + RTc | 191 | 5 | ND | ND |
| 8 | AZT/3TC + SQV/r | 8/5 | 222; 326 | NA | <40 | 145 | Undet | Undet |
| 9 | AZT/3TC + NFVb | 29/4 | 143; 277 | PR + RTc | 499 | 5 | 3.14 × 101 | 1.72 × 101 |
| 10 | AZT/3TC | 15/1 | 297; 273 | NA | <40 | 126 | Undet | Undet |
| 11 | AZT/3TC + IDV/r | 65/51 | 112; 251 | NA | <40 | 346 | 5.19 × 102 | 1.91 |
| 12 | AZT/3TC/ABC | 220/56 | 176; 163 | PR + RTc | 742 | 187 | Undet | 7.25 × 101 |
| 13 | AZT/3TC + IDVb | 218/6 | 121; 102 | PR + RTc | <40 | 5 | 3.73 × 101 | 3.30 × 103 |
| 14 | d4T + 3TC + SQV/rb | 177/120 | 82; 87 | NA | 34,314 | 726 | ND | ND |
| 15 | AZT/3TC + LPV/rb | 67/12 | 120; 84 | PR + RTc | 10,474 | 5 | Undet | Undet |
| 16 | ABC/FTC + LPV/rb | 216/7 | 128; 70 | NA | <40 | 5 | Undet | Undet |
ART refers to the current therapy.
Previous ART regimens included the following: case 1, AZT, ddI, ddC; case 4, ddC, d4T; case 9, ddI, EFV; case 13, d4T; case 14, AZT, ddI; case 15, ddI, d4T, NFV; case 16, AZT.
The following mutations (amino acid change) were found (those mutations previously associated with drug resistance are in bold). Case 3: for PR, P19S, N61D, E65K, L99F; for RT, V5L, K9R, I10V, M11T, E44[K, R, E, G], K68G, R72[K, R], K82R, D86E, Q91[Q, P], P126Q, H162Y, V167I, K173R, K176Q, I179T, E197G, R200K, Y227F, H228Q. Case 7: for PR, Y14[H, Y], N40S, N61D, E65[K, R], K70R; for RT, M11T, E44[E, D], K82R, P126Q, H162Y, V167I, K176Q, M184V, D218[E, D], E219D, D224[N, D], P226[P, S], H228Q, W239[G, W], Q245H, L246W, Q248L, E250D, I251T, K259N, N265I, W266G. Case 9: for PR, E21D, N40S, T56[T, A], V62[A, V], K70R, V71I, L99F; for RT, V5I, M11T, D17[E, D], P51S, D76V, F77L, R78G, E79K, P126Q, S134A, V167I, K176P, I180L, M184V, H228Q, E250G, I251V, K259N, N265I. Case 12: for PR, Y14H, N40S, N41[N, D], I46[I, V], N61[N, D], E65R, D79E; for RT, K9R, I10V, M11T, R22K, K35R, K40R, P51S, K70Q, D86E, R104[K, R], V111I, P126Q, S134A, V167I, K176P, I180[I, L], M184V, S215Y, F221L, D224N, H228Q. Case 13: PR, Y14H, N40S, E65R, K70R, F85L, I89V, L90 M; for RT, A3V, V5M, I10V, M11R, K43R, T53S, T58S, T60[T, P], T88[T, P], P126Q, A138T, V167I, A174T, K176P, I180L, M184V, H228Q, K243[K, R]. Case 15: for PR, K7R, V10I, V22I, V33I, E37D, N40S, I54 M, T56V, N68G, K70R, V71I, M76L, I82F, I89[I, V], T91A, G94[S, G]; for RT, P1[P, L], V5[I, V], I10[I, V], D17[N, D], E48[E, G], A62[A, V], K64[K, R], K65[K, R], A101P, P126Q, P126Q, V135A, Q151M, H162Y, V167I, K176P, I180L, M184V, I189L, V201A, F214L, D218[K, N, E, D], E219[E, D], H228K, V254F.
ND, not done; Undet, undetectable mRNA expression; NA, no amplification; ART, antiretroviral therapy; reverse transcriptase (RT) inhibitors: AZT, zidovudine; 3TC, lamivudine; ABC, abacavir; d4T, stavudine; ddC, zalcitabine; ddI, didanosine; EFV, efavirenz; FTC, emtricitabine; r, ritonavir. Protease (PR) inhibitors: LPV, lopinavir; IDV, indinavir; NFV, nelfinavir; SQV, saquinavir.